转移性去势抵抗性前列腺癌患者的全身治疗:ASCO指南更新
ASCO专家小组系统综述证据后更新mCRPC全身治疗推荐。推荐根据既往治疗选择方案,持续雄激素剥夺治疗,早期进行胚系基因检测和姑息治疗,骨转移者使用骨保护剂;BRCA1/2突变且未接受过ARPI者推荐ARPI联合PARPi,接受过ARPI者推荐多西他赛,接受过ARPI和多西他赛者推荐177Lu-PSMA-617或卡巴他赛,BRCA1/2突变且接受过ARPI者推荐PARPi单药,有症状骨-only疾病推荐镭-223。
要点
- mCRPC后续治疗取决于既往对去势敏感性前列腺癌的全身治疗。
- BRCA1/2突变且未接受过ARPI者推荐ARPI联合PARPi。
- 接受过ARPI者推荐多西他赛;接受过ARPI和多西他赛者推荐177Lu-PSMA-617或卡巴他赛。
核心结论
- mCRPC的治疗选择取决于既往针对去势敏感性前列腺癌的全身治疗。
- 应无限期继续雄激素剥夺治疗。
- 推荐早期进行胚系基因检测和姑息治疗。
研究设计与样本
- ASCO专家小组(包括患者代表)完成系统证据综述并制定推荐。
主要发现
- 根据既往治疗,ARPI(恩扎卢胺、阿比特龙联合泼尼松)、PARPi、化疗药(多西他赛、卡巴他赛)、放射性药物(镭-223、177Lu-PSMA-617)和sipuleucel-T已显示对mCRPC患者的总生存(OS)获益。
- BRCA1/2突变且未接受过ARPI者,PARPi联合ARPI(他拉唑帕利联合恩扎卢胺、奥拉帕利和/或尼拉帕利联合阿比特龙)显示临床获益。
- BRCA1/2突变且接受过ARPI或ARPI后多西他赛者,奥拉帕利显示OS获益。
- 经选择的微卫星不稳定高/错配修复缺陷患者中,帕博利珠单抗显示临床疗效。
关键数值与推荐
- mCRPC且骨转移者应接受骨保护剂。
- BRCA1/2突变且未接受过ARPI者,推荐ARPI联合PARPi。
- 接受过ARPI者,推荐多西他赛化疗。
- 接受过ARPI和多西他赛者,推荐177Lu-PSMA-617或卡巴他赛化疗。
- BRCA1/2突变且接受过ARPI者,推荐PARPi单药;有症状骨-only疾病推荐镭-223。
临床怎么用
- 根据既往去势敏感性前列腺癌的全身治疗选择mCRPC方案。
- mCRPC患者应无限期继续雄激素剥夺治疗。
- 推荐早期进行胚系基因检测和姑息治疗。
- mCRPC伴骨转移者应接受骨保护剂。
局限性
- mCRPC方案最佳序贯的证据缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. RESULTS: Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic agents (docetaxel, cabazitaxel), radiopharmaceuticals (radium 223, 177Lu-prostate-specific membrane antigen [PSMA]-617), and sipuleucel-T have demonstrated an overall survival (OS) benefit for patients with mCRPC. For patients with BRCA1/2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olaparib and/or niraparib + abiraterone) has shown clinical benefit. For patients with BRCA1/2 alterations who received prior ARPI or ARPI followed by docetaxel, olaparib showed OS benefit. In select patients with microsatellite instability-high/mismatch repair-deficient, pembrolizumab showed clinical efficacy. RECOMMENDATIONS: Prior systemic therapy for castration-sensitive prostate cancer will determine subsequent therapy used for mCRPC. Continue androgen-deprivation therapy for patients with mCRPC indefinitely. Early adoption of somatic genetic testing and palliative care is recommended. Patients with mCRPC and bony metastases should receive a bone-protective agent. The panel recommends the combination of ARPI with PARPi in patients with BRCA1/2 alterations who did not receive prior ARPI. For patients who received prior ARPI, the panel recommends docetaxel chemotherapy. The panel recommends 177Lu-PSMA-617 or cabazitaxel chemotherapy for patients who receive prior ARPI and docetaxel chemotherapy. For patients with BRCA1/2 alterations who received prior ARPI, the panel recommends PARPi monotherapy. Radium 223 is recommended for patients with symptomatic bone-only disease. Evidence for optimal sequencing for mCRPC regimens is lacking.Additional information is available at www.asco.org/genitourinary-cancer-guidelines.
引用
- Garje R, Riaz IB, Naqvi SAA, et al. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2025. PMID: 40315400. doi:10.1200/JCO-25-00007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。